Cenobamate was approved by the FDA in 2019 and the EMA in 2021 for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients. Following its approval, studies have continued to further investigate long-term safety and effectiveness.
In this podcast, William E. Rosenfeld and Pavel Klein share new data from open-label extensions and subgroup analyses, as well as practical recommendations for its use in clinical practice.
